Scholarlink

<p>Focused ultrasound ablation surgery (FUAS), a minimally invasive therapeutic strategy, has demonstrated potential in breast cancer treatment but is limited by incomplete tumor irradiation and the damage to normal tissues. Here, we present a novel platform utilizing mesoporous silica nanoparticles (MSNs), functionalized with polyethylene glycol (PEG) and polyethyleneimine (PEI), encapsulating astragaloside IV (AS) and gated with 1-tetradecanol (TD). These NPs (PP@M-TD/AS) attach to <i>Bifidobacterium bifidum</i> (<i>BF</i>) via electrostatic adsorption. Leveraging <i>BF</i>'s tumor-targeting ability in hypoxic microenvironments, the NPs enable specific accumulation in tumor site, facilitating targeted and efficient drug delivery. FUAS-induced thermal effects trigger the phase transition of TD, facilitating on-demand AS release at the tumor site. This approach enhances FUAS-mediated tumor ablation by improving acoustic impedance and ensuring precise drug delivery, leading to significant tumor suppression. Moreover, the system exhibited extended retention at the tumor site and excellent biocompatibility with minimal systemic toxicity. This platform effectively addresses the limitations of FUAS, offering a highly efficient and targeted approach for advancing breast cancer therapy. </p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Bacteria-based drug-loaded mesoporous silica nanoparticles for synergistic FUAS of breast cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月30日

查看全文
  • Mingyang Zhang,
  • Yijun Zhou,
  • Haiyan Yang,
  • Guangrong Zheng,
  • Li Ren,
  • Zhong Zhang,
  • Li Lin,
  • Youqian He,
  • Qi Wang,
  • Jianzhong Zou

摘要

Focused ultrasound ablation surgery (FUAS), a minimally invasive therapeutic strategy, has demonstrated potential in breast cancer treatment but is limited by incomplete tumor irradiation and the damage to normal tissues. Here, we present a novel platform utilizing mesoporous silica nanoparticles (MSNs), functionalized with polyethylene glycol (PEG) and polyethyleneimine (PEI), encapsulating astragaloside IV (AS) and gated with 1-tetradecanol (TD). These NPs (PP@M-TD/AS) attach to Bifidobacterium bifidum (BF) via electrostatic adsorption. Leveraging BF's tumor-targeting ability in hypoxic microenvironments, the NPs enable specific accumulation in tumor site, facilitating targeted and efficient drug delivery. FUAS-induced thermal effects trigger the phase transition of TD, facilitating on-demand AS release at the tumor site. This approach enhances FUAS-mediated tumor ablation by improving acoustic impedance and ensuring precise drug delivery, leading to significant tumor suppression. Moreover, the system exhibited extended retention at the tumor site and excellent biocompatibility with minimal systemic toxicity. This platform effectively addresses the limitations of FUAS, offering a highly efficient and targeted approach for advancing breast cancer therapy.

Graphical Abstract